Nexalin Technology (NXL) Projected to Post Earnings on Friday

Nexalin Technology (NASDAQ:NXL) is expected to issue its results before the market opens on Friday, March 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.08 million for the quarter.

Nexalin Technology Price Performance

NASDAQ NXL opened at $0.44 on Friday. Nexalin Technology has a 1 year low of $0.37 and a 1 year high of $2.57. The stock has a market capitalization of $8.14 million, a PE ratio of -0.66 and a beta of 4.05. The business’s 50-day moving average is $0.57 and its 200 day moving average is $0.89.

Hedge Funds Weigh In On Nexalin Technology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. PEAK6 LLC bought a new stake in shares of Nexalin Technology during the 4th quarter valued at $266,000. Renaissance Technologies LLC lifted its position in Nexalin Technology by 119.2% during the 4th quarter. Renaissance Technologies LLC now owns 122,100 shares of the company’s stock valued at $68,000 after acquiring an additional 66,400 shares during the period. Geode Capital Management LLC boosted its stake in Nexalin Technology by 23.4% during the fourth quarter. Geode Capital Management LLC now owns 150,274 shares of the company’s stock worth $84,000 after acquiring an additional 28,454 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in Nexalin Technology in the third quarter worth about $57,000. Hedge funds and other institutional investors own 0.65% of the company’s stock.

Analyst Ratings Changes

NXL has been the topic of several research analyst reports. Wall Street Zen cut Nexalin Technology from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Nexalin Technology in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.00.

Nexalin Technology Company Profile

Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S.